You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthotoin
Accession NumberDB00754  (APRD00962)
TypeSmall Molecule
GroupsApproved
DescriptionEthotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
Structure
Thumb
Synonyms
(+-)-3-Ethyl-5-phenylhydantoin
1-Ethyl-2,5-dioxo-4-phenylimidazolidine
3-Ethyl-5-phenyl-2,4-imidazolidinedione
3-Ethyl-5-phenyl-imidazolidine-2,4-dione
3-Ethyl-5-phenylhydantoin
3-Ethyl-5-phenylimidazolidin-2,4-dione
Ethotoin
Ethotoïne
Ethotoinum
Etotoina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Peganonetablet250 mg/1oralRECORDATI RARE DISEASES, INC.1957-04-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AccenonDainippon Sumitomo
PegoanoneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII46QG38NC4U
CAS number86-35-1
WeightAverage: 204.2252
Monoisotopic: 204.089877638
Chemical FormulaC11H12N2O2
InChI KeyInChIKey=SZQIFWWUIBRPBZ-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
IUPAC Name
3-ethyl-5-phenylimidazolidine-2,4-dione
SMILES
CCN1C(=O)NC(C1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassImidazolidines
Direct ParentPhenylhydantoins
Alternative Parents
Substituents
  • 5-phenylhydantoin
  • Phenylimidazolidine
  • Ureide
  • Benzenoid
  • Monocyclic benzene moiety
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.
PharmacodynamicsEthotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.
Mechanism of actionThe mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation.
Related Articles
AbsorptionFairly rapidly absorbed, however, the extent of oral absorption is not known.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites.

SubstrateEnzymesProduct
Ethotoin
Not Available
p-Hydroxyl-ethotoinDetails
Route of eliminationNot Available
Half life3 to 9 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9936
Caco-2 permeable+0.5629
P-glycoprotein substrateNon-substrate0.592
P-glycoprotein inhibitor INon-inhibitor0.8358
P-glycoprotein inhibitor IINon-inhibitor0.9401
Renal organic cation transporterNon-inhibitor0.8532
CYP450 2C9 substrateNon-substrate0.7507
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7383
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.914
CYP450 2D6 inhibitorNon-inhibitor0.9619
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8591
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8483
Ames testNon AMES toxic0.7056
CarcinogenicityNon-carcinogens0.8655
BiodegradationNot ready biodegradable0.8423
Rat acute toxicity2.1653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.886
hERG inhibition (predictor II)Non-inhibitor0.8724
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Lundbeck inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral250 mg/1
Prices
Unit descriptionCostUnit
Peganone 250 mg tablet1.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point94 °CPhysProp
water solubility5280 mg/LNot Available
logP1.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility2.38 mg/mLALOGPS
logP1.11ALOGPS
logP1.07ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)11.29ChemAxon
pKa (Strongest Basic)-8.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.41 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity55.05 m3·mol-1ChemAxon
Polarizability20.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-6920000000-01714c9dcd6c4cf02362View in MoNA
References
Synthesis Reference

Close, W.J.; U.S. Patent 2,793,157; May 21, 1957; assigned to Abbott Laboratories.

General References
  1. SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. [PubMed:13317788 ]
External Links
ATC CodesN03AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethotoin.
AcenocoumarolEthotoin may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethotoin.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethotoin.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Ethotoin.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethotoin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethotoin.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethotoin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethotoin.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethotoin.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethotoin.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethotoin.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethotoin.
AmoxapineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethotoin.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ethotoin.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethotoin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ethotoin.
AzelastineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethotoin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethotoin.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethotoin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethotoin.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ethotoin.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
BrimonidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin.
BrompheniramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ethotoin.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethotoin.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ethotoin.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethotoin.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethotoin.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ethotoin.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethotoin.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ethotoin.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethotoin.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethotoin.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethotoin.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ethotoin.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethotoin.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethotoin.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethotoin.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethotoin.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethotoin.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethotoin.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethotoin.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethotoin.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethotoin.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethotoin.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ethotoin.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethotoin.
CitalopramThe risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ethotoin.
ClidiniumThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethotoin.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ethotoin.
ClomipramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethotoin.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethotoin.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethotoin.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethotoin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethotoin.
CyclizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethotoin.
DantroleneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethotoin.
DapoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ethotoin.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethotoin.
DesipramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ethotoin.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethotoin.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethotoin.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethotoin.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethotoin.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethotoin.
DicoumarolEthotoin may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethotoin.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethotoin.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethotoin.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethotoin.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethotoin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ethotoin.
DoxepinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
DoxylamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethotoin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethotoin.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ethotoin.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethotoin.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ethotoin.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethotoin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethotoin.
EscitalopramThe risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethotoin.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethotoin.
EthanolEthotoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ethotoin.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.
Ethyl biscoumacetateEthotoin may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethotoin.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethotoin.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethotoin.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ethotoin.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ethotoin.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ethotoin.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethotoin.
EtoperidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethotoin.
EzogabineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethotoin.
FenfluramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethotoin.
FexofenadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethotoin.
FlunarizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethotoin.
FluoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethotoin.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethotoin.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethotoin.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethotoin.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ethotoin.
FluvoxamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ethotoin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethotoin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethotoin is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethotoin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethotoin.
GuanfacineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethotoin.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethotoin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethotoin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethotoin.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethotoin.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
HydroxyzineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethotoin.
IndalpineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethotoin.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethotoin.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethotoin.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethotoin.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethotoin.
LevetiracetamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethotoin.
LevocabastineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethotoin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethotoin.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethotoin.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethotoin.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ethotoin.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethotoin.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethotoin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethotoin.
Lu AA21004The risk or severity of adverse effects can be increased when Ethotoin is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ethotoin.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ethotoin.
MefloquineThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethotoin.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ethotoin.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethotoin.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethotoin.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethotoin.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethotoin.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ethotoin.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethotoin.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethotoin.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethotoin.
MethsuximideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethotoin.
MetyrosineEthotoin may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.
MilnacipranThe risk or severity of adverse effects can be increased when Ethotoin is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
MirtazapineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethotoin.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ethotoin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethotoin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
NabiloneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethotoin.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethotoin.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethotoin.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ethotoin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethotoin.
OlanzapineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethotoin.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ethotoin.
OrlistatThe serum concentration of Ethotoin can be decreased when it is combined with Orlistat.
OrphenadrineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethotoin.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethotoin.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethotoin.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethotoin.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethotoin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethotoin.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethotoin.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethotoin.
ParaldehydeEthotoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ethotoin.
ParoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethotoin.
PerampanelThe risk or severity of adverse effects can be increased when Ethotoin is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethotoin.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethotoin.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethotoin.
PhenindioneEthotoin may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethotoin.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ethotoin.
PhenprocoumonEthotoin may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ethotoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethotoin.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethotoin.
PipotiazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.
PramipexoleEthotoin may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethotoin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethotoin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethotoin.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethotoin.
PrimidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethotoin.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.
PromethazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethotoin.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethotoin.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ethotoin.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ethotoin.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethotoin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.
RamelteonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethotoin.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethotoin.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethotoin.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ethotoin.
RopiniroleEthotoin may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethotoin.
RotigotineEthotoin may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethotoin.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethotoin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethotoin.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ethotoin.
SertralineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethotoin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Ethotoin.
StiripentolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethotoin.
SuvorexantThe risk or severity of adverse effects can be increased when Ethotoin is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethotoin.
TetrabenazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethotoin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethotoin.
ThalidomideEthotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethotoin.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethotoin.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethotoin.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethotoin.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethotoin.
TiagabineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ethotoin.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethotoin.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethotoin.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethotoin.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethotoin.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethotoin.
TrazodoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethotoin.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethotoin.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethotoin.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethotoin.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethotoin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethotoin.
VigabatrinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vortioxetine.
WarfarinEthotoin may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ethotoin.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethotoin.
ZiconotideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ethotoin.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethotoin.
ZonisamideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethotoin.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ethotoin.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethotoin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK: Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004 Apr;21(5):635-44. [PubMed:15066664 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23